Skip to main content

News stories

Review led by researchers highlights potential treatment for alcohol use disorder

Published on 18/02/2026

Dr Pouya Ebrahimi, Specialty Registrar in Cardiology at Good Hope Hospital
Dr Pouya Ebrahimi, Specialty Registrar in Cardiology at Good Hope Hospital

University Hospitals Birmingham colleagues are among the authors of an international research paper recently published in The Lancet. Led by Dr Pouya Ebrahimi, Specialty Registrar in Cardiology, and Dr Yash Kachela, Medical Student Undergraduate, the study examines how diabetes and weight management medicines may support people living with alcohol use disorder.

Alcohol use disorder is a medical condition characterised by an impaired ability to stop or control alcohol use despite adverse social, occupational, or health consequences. It is common, yet only a small proportion of people receive effective treatment.

Medicines called GLP-1 receptor agonists, such as semaglutide and liraglutide, were originally developed to treat metabolic diseases like diabetes and to help with weight management. In recent years, patients and clinicians have increasingly reported that those taking GLP-1 medications often notice a reduced desire to drink alcohol.

To investigate this emerging pattern, an international research team, spanning the UK, Denmark and the United States, reviewed all available evidence on the effects of GLP-1 medicines on alcohol use behaviour. This included randomised trials, large population-based studies, and real-world data from more than five million people.

Across the studies, people taking GLP-1 medicines experienced fewer cravings, drank less frequently, and consumed fewer units when they did drink. They were also less likely to return to heavy drinking or develop alcohol-related health problems.

Brain imaging studies suggest that these medicines may reduce the rewarding effects of alcohol and help dampen urges triggered by cues. The strongest benefits were seen with semaglutide and liraglutide, particularly among individuals with obesity or type 2 diabetes.

Overall, these findings show that GLP-1 medicines have consistent and meaningful effects on reducing alcohol intake and relapse risk. While they could become an important new option for supporting people with alcohol use disorder, larger clinical trials specifically designed to test this are still needed.

Dr Pouya Ebrahimi said: “This research provides important evidence that GLP-1 receptor agonists could have a meaningful role beyond metabolic disease. Given current treatments for alcohol use disorder are often limited in effectiveness, these findings could pave the way for more personalised approaches that target the underlying biology of the condition.

“The next steps will be to carry out further clinical trials to confirm how well the treatment works, identify the best dose, and understand which patient groups are most likely to benefit.”

This article is part of our research news collection.

Visit our dedicated research site for more research and innovation news from UHB.

More news

New energy centre powers a greener future for Solihull Hospital

New energy centre powers a greener future for Solihull Hospital

The hospital is set to reduce its carbon emissions by 1,812 tonnes every year following the completion of a new energy centre and energy-efficiency improvements.
Microsoft outage

Microsoft outage

Due to the global issues affecting Microsoft, we are currently experiencing issues with some of our IT systems, including sending and receiving emails.
Major investment to bring care closer to home in Solihull

Major investment to bring care closer to home in Solihull

More than £5 million of NHS growth funding is being invested in community health and care services in Solihull. The £5.28 million investment will help local people get earlier, more joined-up support closer to home, helping them stay well and independent for longer.
Read more news